Similar articles for PMID: 23457168

Year	Number of Results
2010	1
2011	2
2012	4
2013	18
2014	9
2015	16
2016	7
2017	11
2018	15
2019	14
2020	10
2021	7
2022	1
2023	1
2024	0

1

The impact of personalised therapies on respiratory medicine.

Elborn JS. Elborn JS. Eur Respir Rev. 2013 Mar 1;22(127):72-4. doi: 10.1183/09059180.00008212. Eur Respir Rev. 2013. PMID: 23457168 Free PMC article.

2

Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation.

Sermet-Gaudelus I. Sermet-Gaudelus I. Eur Respir Rev. 2013 Mar 1;22(127):66-71. doi: 10.1183/09059180.00008512. Eur Respir Rev. 2013. PMID: 23457167 Free PMC article. Review.

3

Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.

Kuk K, Taylor-Cousar JL. Kuk K, et al. Ther Adv Respir Dis. 2015 Dec;9(6):313-26. doi: 10.1177/1753465815601934. Epub 2015 Sep 28. Ther Adv Respir Dis. 2015. PMID: 26416827 Free article. Review.

4

Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.

Skilton M, Krishan A, Patel S, Sinha IP, Southern KW. Skilton M, et al. Cochrane Database Syst Rev. 2019 Jan 7;1(1):CD009841. doi: 10.1002/14651858.CD009841.pub3. Cochrane Database Syst Rev. 2019. PMID: 30616300 Free PMC article.

5

Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.

Kotha K, Clancy JP. Kotha K, et al. Ther Adv Respir Dis. 2013 Oct;7(5):288-96. doi: 10.1177/1753465813502115. Epub 2013 Sep 3. Ther Adv Respir Dis. 2013. PMID: 24004658 Free article. Review.

6

Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.

Patel S, Sinha IP, Dwan K, Echevarria C, Schechter M, Southern KW. Patel S, et al. Cochrane Database Syst Rev. 2015 Mar 26;(3):CD009841. doi: 10.1002/14651858.CD009841.pub2. Cochrane Database Syst Rev. 2015. PMID: 25811419 Updated. Review.

7

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.

Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, Sagel SD, Khan U, Mayer-Hamblett N, Van Dalfsen JM, Joseloff E, Ramsey BW; GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Rowe SM, et al. Am J Respir Crit Care Med. 2014 Jul 15;190(2):175-84. doi: 10.1164/rccm.201404-0703OC. Am J Respir Crit Care Med. 2014. PMID: 24927234 Free PMC article.

8

Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.

Davies J, Sheridan H, Bell N, Cunningham S, Davis SD, Elborn JS, Milla CE, Starner TD, Weiner DJ, Lee PS, Ratjen F. Davies J, et al. Lancet Respir Med. 2013 Oct;1(8):630-638. doi: 10.1016/S2213-2600(13)70182-6. Epub 2013 Sep 10. Lancet Respir Med. 2013. PMID: 24461666 Clinical Trial.

9

Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis.

Derichs N. Derichs N. Eur Respir Rev. 2013 Mar 1;22(127):58-65. doi: 10.1183/09059180.00008412. Eur Respir Rev. 2013. PMID: 23457166 Free PMC article. Review.

10

Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.

Harris JK, Wagner BD, Zemanick ET, Robertson CE, Stevens MJ, Heltshe SL, Rowe SM, Sagel SD. Harris JK, et al. Ann Am Thorac Soc. 2020 Feb;17(2):212-220. doi: 10.1513/AnnalsATS.201907-493OC. Ann Am Thorac Soc. 2020. PMID: 31604026 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

105 results

Results by year